Delcath Systems, Inc.  

(Public, NASDAQ:DCTH)   Watch this stock  
Find more results for DCTH
+0.002 (0.65%)
Feb 12 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.25 - 0.28
52 week 0.25 - 1.92
Open 0.27
Vol / Avg. 21,310.00/172,681.00
Mkt cap 5.60M
P/E     -
Div/yield     -
EPS -1.05
Shares 21.76M
Beta 1.77
Inst. own 18%
Feb 11, 2016
Delcath Systems Inc at Source Capital Group Disruptive Growth & Healthcare Conference
Feb 8, 2016
Delcath Systems Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference - Webcast
Jan 20, 2016
Delcath Systems Inc at Noble Financial Capital Markets Equity Conference
Nov 17, 2015
Delcath Systems Inc Conference Call to discuss Business Update - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -607.02% -1625.91%
Operating margin -914.79% -1805.80%
EBITD margin - -1712.25%
Return on average assets -52.57% -57.12%
Return on average equity -72.97% -72.05%
Employees 25 -
CDP Score - -


1301 Avenue of the Americas Fl 43
NEW YORK, NY 10019-6022
United States - Map
+1-212-4892100 (Phone)
+1-212-4892102 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. The Company's principal focus is on the treatment of primary and metastatic liver cancers. The Company’s product Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) is designed to administer high dose chemotherapy to the liver, while controlling the systemic exposure to those agents. In the United States, Melphalan/HDS is considered a combination drug and device product, and is regulated as a drug by the United States Food and Drug Administration (FDA). In Europe, the Company’s system to deliver and filter melphalan hydrochloride is marketed as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan (CHEMOSAT). It has authorization to affix a CE Mark for Generation Two CHEMOSAT. The right to affix the CE Mark allows the Company to market CHEMOSAT in Europe.

Officers and directors

Roger G. Stoll Ph.D. Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Jennifer K. Simpson Ph.D. President, Chief Executive Officer, Director
Age: 46
Bio & Compensation  - Reuters
Barbra C. Keck Principal Financial Officer, Senior Vice President - Finance, Principal Accounting Officer, Secretary
Age: 37
Bio & Compensation  - Reuters
John Purpura Executive Vice President - Regulatory Affairs and Quality Assurance
Age: 53
Bio & Compensation  - Reuters
Harold S. Koplewicz M.D. Independent Director
Age: 62
Bio & Compensation  - Reuters
Dennis H. Langer M.D., J.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Laura A. Philips Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
William Dodge Rueckert Independent Director
Age: 62
Bio & Compensation  - Reuters
Marco Taglietti M.D. Independent Director
Age: 55
Bio & Compensation  - Reuters